Back to results
US 2003/0149075 A1Published application
Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
AssigneePfizer Inc.
InventorDaniel Ray Arenson
Life of this patent
Estimating the term…
Abstract
Formulations containing a sodium hydrogen exchanger-1 (NHE-1) inhibitor for prevention of, inter alia, perioperative myocardial ischemic injury in mammals and a process for increasing the solubility of said inhibitor with methanesulfonic acid.
Claims27
A method for increasing the solubility of a compound of Formula I,
- 5
- or its mesylate salt, comprising treating the compound of formula I with methanesulfonic acid in the presence of an aqueous pharmaceutically acceptable diluent, forming a solution having a pH in the range of 2 to 3.5.
A pharmaceutical composition comprising a mesylate salt of compound of Formula I,
- 6
- an aqueous pharmaceutically acceptable diluent and methanesulfonic acid, wherein said composition has a pH in the range of 2 to 3.5.
A kit comprising:
- (a) a therapeutically effective amount of a lyophilized pharmaceutical composition comprising a mesylate salt of a compound of Formula I,
- 7
- (b) a pharmaceutically acceptable aqueous diluent;
- and
- (c) a first and second container means for containing said composition (a) and said diluent (b), wherein said first container is adapted to receive said diluent from said second container.
2 more elements
Dependencies are inferred from the claim text.